Real-world outcomes of patients with relapsed/refractory large B-cell lymphoma receiving second-line therapy in England

被引：0

作者：

Fox, Christopher P. ^{[1
]}

Townsend, William ^{[2
]}

Gribben, John G. ^{[3
]}

Menne, Tobias ^{[4
]}

Kalakonda, Nagesh ^{[5
]}

Williams, Paula ^{[6
]}

Toron, Farah ^{[6
]}

Tyas, Emma ^{[7
]}

Cooper, Miranda ^{[7
]}

Rickards, Joshua ^{[7
]}

Radford, John ^{[8
,9
]}

机构：

[1] Univ Nottingham, Sch Med, Nottingham, England

[2] Univ Coll London Hosp, NHS Fdn Trust, London, England

[3] Barts Hlth NHS Trust, Barts Canc Inst, London, England

[4] Newcastle Tyne Hosp, NHS Fdn Trust, Newcastle Upon Tyne, England

[5] Univ Liverpool, Mol & Clin Canc Med, Liverpool, England

[6] Bristol Myers Squibb, Uxbridge, England

[7] Lumanity, Farnham, England

[8] Christie NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester, England

[9] Univ Manchester, Manchester, England

来源：

EJHAEM | 2024年 / 5卷 / 05期

关键词：

ASCT; LBCL; outcomes; real-world evidence; TRANSPLANTATION;

D O I：

10.1002/jha2.970

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Autologous stem-cell transplantation (ASCT) is standard therapy for relapsed/refractory large B-cell lymphoma (R/R LBCL), but many patients are either ineligible or unable to receive it. This retrospective study characterized outcomes in R/R LBCL, delineated by eligibility for, and receipt of, ASCT. Median progression-free survival (PFS) and event-free survival (EFS) for patients undergoing ASCT were 35.2 and 31.6 months (overall survival [OS] not reached). Median PFS, EFS, and OS were 4.3, 4.3, and 6.9 months for ineligible patients, and 2.7, 2.6, and 9.4 months for those eligible for but unable to receive ASCT. This highlights an unmet need for alternative therapies in patients unable to receive ASCT.

引用

页码：992 / 997

页数：6

共 50 条

[21] Retrospective Analysis of Real-World Outcomes in Older Adult Patients With Diffuse Large B-Cell Lymphoma
Jobanputra, Kunal
Nayak, Lingaraj
Jain, Hasmukh
Bonda, V. N. Avinash
Thorat, Jayashree
Bagal, Bhausaheb
Sengar, Manju
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S372 - S373
[22] Single center, real-world retrospective study of CAR-T cell therapy for relapsed/refractory large B-cell lymphoma beyond second line: five-year results at the University Hospitals Leuven
Brijs, Jan
Van Ham, Jonas
Dubois, Benedicte
Sinap, Franky
Vergote, Vibeke
Dierickx, Daan
Vandenberghe, Peter
ACTA CLINICA BELGICA, 2024, 79 (04) : 276 - 284
[23] Real-World Survival Outcomes of Patients with Malignant Pleural Mesothelioma by Choice of Second-line Therapy
Kerrigan, K.
Chipman, J.
Jo, Y. J.
Haaland, B.
Johnson, E.
Puri, S.
Varghese, T.
Akerley, W.
Patel, S.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S199 - S199
[24] Real-World Evidence of Relapsed/Refractory Mantle Cell Lymphoma Patients and Treatments: A Systematic Review
Sancho, Juan-Manuel
Sorigue, Marc
Rubio-Azpeitia, Eva
JOURNAL OF BLOOD MEDICINE, 2024, 15 : 239 - 254
[25] Burden of Illness and Treatment Patterns in Second-line Large B-cell Lymphoma
Snider, Julia Thornton
McMorrow, Donna
Song, Xue
Diakun, David
Wade, Sally W.
Cheng, Paul
CLINICAL THERAPEUTICS, 2022, 44 (04) : 521 - +
[26] Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Schuster, Stephen J.
Bishop, Michael R.
Tam, Constantine S.
Waller, Edmund K.
Borchmann, Peter
McGuirk, Joseph P.
Jaeger, Ulrich
Jaglowski, Samantha
Andreadis, Charalambos
Westin, Jason R.
Fleury, Isabelle
Bachanova, Veronika
Foley, S. Ronan
Ho, P. Joy p
Mielke, Stephan
Magenau, John M.
Holte, Harald
Pantano, Serafino
Pacaud, Lida B.
Awasthi, Rakesh
Chu, Jufen
Anak, Ozlem
Salles, Gilles
Maziarz, Richard T.
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (01) : 45 - 56
[27] Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study
Van den Neste, E.
Schmitz, N.
Mounier, N.
Gill, D.
Linch, D.
Trneny, M.
Milpied, N.
Radford, J.
Ketterer, N.
Shpilberg, O.
Duehrsen, U.
Ma, D.
Briere, J.
Thieblemont, C.
Salles, G.
Moskowitz, C. H.
Glass, B.
Gisselbrecht, C.
BONE MARROW TRANSPLANTATION, 2016, 51 (01) : 51 - 57
[28] Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma
Villa, Diego
Jiang, Aixiang
Visco, Carlo
Crosbie, Nicola
Mcculloch, Rory
Buege, Michael J.
Kumar, Anita
Bond, David A.
Paludo, Jonas
Maurer, Matthew J.
Thanarajasingam, Gita
Lewis, Katharine L.
Cheah, Chan Y.
Baech, Joachim
El-Galaly, Tarec C.
Kugathasan, Laveniya
Scott, David W.
Gerrie, Alina S.
Lewis, David
BLOOD ADVANCES, 2023, 7 (16) : 4576 - 4585
[29] Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma
Epperla, Narendranath
Lucero, Melanie
Bailey, Tom
Mirams, Laura
Cheung, Jolenta
Amet, Mona
Milligan, Gary
Chen, Lei
BLOOD CANCER JOURNAL, 2024, 14 (01):
[30] Choosing a CAR for Relapsed/Refractory Large B-cell Lymphoma
Abramson, Jeremy S.
TRANSPLANTATION AND CELLULAR THERAPY, 2022, 28 (10): : 621 - 622

← 1 2 3 4 5 →